Indivior Pharmaceuticals, Inc.
INDV
$33.34
$0.742.27%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.29% | -0.17% | 2.35% | 4.18% | 8.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.29% | -0.17% | 2.35% | 4.18% | 8.78% |
| Cost of Revenue | -10.81% | -9.91% | -0.50% | 31.79% | 27.59% |
| Gross Profit | 7.76% | 1.96% | 2.96% | -0.84% | 5.22% |
| SG&A Expenses | -4.15% | -1.16% | -3.86% | -0.50% | 5.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 20.00% | -150.00% | 37.50% | 37.50% | 37.50% |
| Total Operating Expenses | -8.09% | -5.93% | -3.99% | 4.45% | 8.93% |
| Operating Income | 48.09% | 20.78% | 29.09% | 3.24% | 8.26% |
| Income Before Tax | 1,090.00% | 283.96% | 159.31% | 104.44% | 113.42% |
| Income Tax Expenses | 123.08% | 546.67% | 215.94% | 156.52% | 165.00% |
| Earnings from Continuing Operations | 2,885.71% | 240.66% | 143.55% | 93.75% | 105.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2,885.71% | 240.66% | 143.55% | 93.75% | 105.43% |
| EBIT | 48.09% | 20.78% | 29.09% | 3.24% | 8.26% |
| EBITDA | 44.73% | 16.91% | 23.43% | 0.37% | 5.36% |
| EPS Basic | 2,582.11% | 258.73% | 147.72% | 99.13% | 106.82% |
| Normalized Basic EPS | 58.96% | 22.09% | 24.81% | -1.73% | 0.93% |
| EPS Diluted | 2,912.50% | 255.21% | 147.09% | 98.12% | 105.77% |
| Normalized Diluted EPS | 56.00% | 20.52% | 24.05% | -1.31% | 2.13% |
| Average Basic Shares Outstanding | -5.90% | -8.14% | -7.82% | -6.53% | -4.45% |
| Average Diluted Shares Outstanding | -4.50% | -7.11% | -7.17% | -6.85% | -5.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |